Selecting Safe Chemotherapy Regimens in Older Breast Cancer Patients

Video

This video reviews the evidence for safe and effective chemotherapy regimens in older patients with breast cancer and highlights the need for geriatric assessment in this population.

In breast cancer trials, most chemotherapy regimens are studied in younger, healthier patients. In practice, many of these regimens have been shown to be too toxic for older women, with higher rates of hospitalization among these patients.

In this video, Hans Wildiers, MD, PhD, of University Hospitals Leuven in Belgium, reviews some of the regimens that are too toxic, highlights one regimen shown to be feasible, and discusses the need for geriatric assessment in this population.  

Recent Videos
7 experts are featured in this series.
7 experts are featured in this series.
2 KOLs are featured in this series.
Patients with high-risk markers may especially benefit from the addition of daratumumab to lenalidomide as maintenance therapy for NDMM.
A machine learning method for scoring tumor-infiltrating lymphocytes may address variability in pathologist measurements.
Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.
Related Content
Apalutamide plus stereotactic radiotherapy may be effective for certain patients with recurrent prostate cancer following radical prostatectomy.

PAM50 Biomarker May Predict Apalutamide Efficacy in Prostate Cancer

Russ Conroy
September 29th 2025
Article

Apalutamide plus stereotactic radiotherapy may be effective for certain patients with recurrent prostate cancer following radical prostatectomy.

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

Gary Steinberg, MD
September 29th 2025
Podcast

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Acknowledging Mortality and Death in Cancer Care

Acknowledging Mortality and Death in Cancer Care

Ariana Pelosci
September 29th 2025
Article

In the oncology setting, having discussions about mortality and death may be daunting for patients, but is vital and inevitable.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

The addition of certepetide to a FOLFIRINOX-based regimen was safe in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma.

Certepetide/FOLFIRINOX Displays Encouraging Preliminary Feasibility in PDAC

Roman Fabbricatore
September 29th 2025
Article

The addition of certepetide to a FOLFIRINOX-based regimen was safe in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma.

Laser vision correction. A patient and team of surgeons in the operating room during ophthalmic surgery. Eyelid speculum. Lasik treatment.| Image Credit: © romaset-stock.adobe.com

Brachytherapy/Vitrectomy, Silicone Oil Confer Positive Uveal Melanoma DMFS

Ariana Pelosci
September 28th 2025
Article

An 80% disease metastasis-free survival rate occurred in those with uveal melanoma who received a brachytherapy plaque with vitrectomy and silicone oil.